The pivot: Turnstone Biologics opens a new chapter with a switch to clinical development and a new venture round to pay for it
In biotech, most startups get about 5 years to get their preclinical act in order and jump into human studies before the backers get restive and start looking for the exits. At the 2015-founded Turnstone Biologics, they hit that line. But instead of losing its investors’ interest, it’s been picking up speed and backers.
Now, with a lead oncolytic virus in an early-stage study and a second therapy from the TIL side poised for an IND, the team under CEO Sammy Farah has changed the story to clinical development. And they scored an $80 million Series D from a broad syndicate to get this new chapter under way in style.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.